A mononuclear cell dose of 3 x 105/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation

R. J. Smith, J. W. Sweetenham

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma. PBPCs were mobilized with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), and each patient underwent two (n = 20) or three (n = 15) apheresis procedures. Median cell yields were 5.03 x 108 MNC/kg (range 1.59-15.70 x 108) and 73.10 x 104 CFU-GM/kg (range 0.09-346.72 x 104). All patients achieved hematologic recovery. Median days to neutrophils ≥ 0.1 x 109/L, neutrophils ≥ 0.5 x 109/L, and platelets ≥ 25 x 109/L were 11 (range 8-15), 13 (range 10-37), and 11 (range 7-41), respectively. A close correlation was observed between the MNC and CFU-GM dose (r = 0.79, p < 0.0001). We have previously defined a minimum threshold CFU-GM dose of 20 x 104/kg for patients undergoing high-dose therapy. This corresponds with an MNC dose of 3 x 108/kg. Comparison of engraftment in patients receiving 3 x 108 MNC/kg with those receiving lower doses demonstrated significantly longer times to recovery of neutrophils to ≥ 0.5 x 109/L and platelets to ≥ 25 x 109/L. All patients receiving an MNC dose of ≥ 3 x 108/kg achieved neutrophil and platelet recovery by days 12 and 24, respectively. These preliminary data demonstrate that for patients with lymphoma undergoing PBPC mobilization according to this protocol and treated with BEAM chemotherapy, assessment of MNC dose alone is sufficient to predict early hematologic recovery. Additional assays such as CFU-GM or CD34+ cell counts may not be necessary if this MNC dose is reinfused.

Original languageEnglish (US)
Pages (from-to)1581-1588
Number of pages8
JournalExperimental Hematology
Volume23
Issue number14
StatePublished - Dec 1 1995
Externally publishedYes

Fingerprint

Carmustine
Melphalan
Cytarabine
Cell Transplantation
Etoposide
Lymphoma
Blood Cells
Stem Cells
Granulocyte-Macrophage Progenitor Cells
Neutrophils
Blood Platelets
Drug Therapy
Blood Component Removal
Granulocyte Colony-Stimulating Factor
Cyclophosphamide
Cell Count
Transplants

Keywords

  • CFU-GM
  • Engraftment
  • Lymphoma
  • MNC
  • PBPC transplantation

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

@article{9434597b221a447e9c51df89b3393c57,
title = "A mononuclear cell dose of 3 x 105/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation",
abstract = "We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma. PBPCs were mobilized with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), and each patient underwent two (n = 20) or three (n = 15) apheresis procedures. Median cell yields were 5.03 x 108 MNC/kg (range 1.59-15.70 x 108) and 73.10 x 104 CFU-GM/kg (range 0.09-346.72 x 104). All patients achieved hematologic recovery. Median days to neutrophils ≥ 0.1 x 109/L, neutrophils ≥ 0.5 x 109/L, and platelets ≥ 25 x 109/L were 11 (range 8-15), 13 (range 10-37), and 11 (range 7-41), respectively. A close correlation was observed between the MNC and CFU-GM dose (r = 0.79, p < 0.0001). We have previously defined a minimum threshold CFU-GM dose of 20 x 104/kg for patients undergoing high-dose therapy. This corresponds with an MNC dose of 3 x 108/kg. Comparison of engraftment in patients receiving 3 x 108 MNC/kg with those receiving lower doses demonstrated significantly longer times to recovery of neutrophils to ≥ 0.5 x 109/L and platelets to ≥ 25 x 109/L. All patients receiving an MNC dose of ≥ 3 x 108/kg achieved neutrophil and platelet recovery by days 12 and 24, respectively. These preliminary data demonstrate that for patients with lymphoma undergoing PBPC mobilization according to this protocol and treated with BEAM chemotherapy, assessment of MNC dose alone is sufficient to predict early hematologic recovery. Additional assays such as CFU-GM or CD34+ cell counts may not be necessary if this MNC dose is reinfused.",
keywords = "CFU-GM, Engraftment, Lymphoma, MNC, PBPC transplantation",
author = "Smith, {R. J.} and Sweetenham, {J. W.}",
year = "1995",
month = "12",
day = "1",
language = "English (US)",
volume = "23",
pages = "1581--1588",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - A mononuclear cell dose of 3 x 105/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation

AU - Smith, R. J.

AU - Sweetenham, J. W.

PY - 1995/12/1

Y1 - 1995/12/1

N2 - We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma. PBPCs were mobilized with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), and each patient underwent two (n = 20) or three (n = 15) apheresis procedures. Median cell yields were 5.03 x 108 MNC/kg (range 1.59-15.70 x 108) and 73.10 x 104 CFU-GM/kg (range 0.09-346.72 x 104). All patients achieved hematologic recovery. Median days to neutrophils ≥ 0.1 x 109/L, neutrophils ≥ 0.5 x 109/L, and platelets ≥ 25 x 109/L were 11 (range 8-15), 13 (range 10-37), and 11 (range 7-41), respectively. A close correlation was observed between the MNC and CFU-GM dose (r = 0.79, p < 0.0001). We have previously defined a minimum threshold CFU-GM dose of 20 x 104/kg for patients undergoing high-dose therapy. This corresponds with an MNC dose of 3 x 108/kg. Comparison of engraftment in patients receiving 3 x 108 MNC/kg with those receiving lower doses demonstrated significantly longer times to recovery of neutrophils to ≥ 0.5 x 109/L and platelets to ≥ 25 x 109/L. All patients receiving an MNC dose of ≥ 3 x 108/kg achieved neutrophil and platelet recovery by days 12 and 24, respectively. These preliminary data demonstrate that for patients with lymphoma undergoing PBPC mobilization according to this protocol and treated with BEAM chemotherapy, assessment of MNC dose alone is sufficient to predict early hematologic recovery. Additional assays such as CFU-GM or CD34+ cell counts may not be necessary if this MNC dose is reinfused.

AB - We have assessed the potential use of the mononuclear cell (MNC) content as the sole assessment of graft quality in 35 patients receiving BEAM (carmustine, etoposide, cytosine arabinoside, melphalan) chemotherapy and autologous peripheral blood progenitor cell (PBPC) transplantation for malignant lymphoma. PBPCs were mobilized with cyclophosphamide and granulocyte colony-stimulating factor (G-CSF), and each patient underwent two (n = 20) or three (n = 15) apheresis procedures. Median cell yields were 5.03 x 108 MNC/kg (range 1.59-15.70 x 108) and 73.10 x 104 CFU-GM/kg (range 0.09-346.72 x 104). All patients achieved hematologic recovery. Median days to neutrophils ≥ 0.1 x 109/L, neutrophils ≥ 0.5 x 109/L, and platelets ≥ 25 x 109/L were 11 (range 8-15), 13 (range 10-37), and 11 (range 7-41), respectively. A close correlation was observed between the MNC and CFU-GM dose (r = 0.79, p < 0.0001). We have previously defined a minimum threshold CFU-GM dose of 20 x 104/kg for patients undergoing high-dose therapy. This corresponds with an MNC dose of 3 x 108/kg. Comparison of engraftment in patients receiving 3 x 108 MNC/kg with those receiving lower doses demonstrated significantly longer times to recovery of neutrophils to ≥ 0.5 x 109/L and platelets to ≥ 25 x 109/L. All patients receiving an MNC dose of ≥ 3 x 108/kg achieved neutrophil and platelet recovery by days 12 and 24, respectively. These preliminary data demonstrate that for patients with lymphoma undergoing PBPC mobilization according to this protocol and treated with BEAM chemotherapy, assessment of MNC dose alone is sufficient to predict early hematologic recovery. Additional assays such as CFU-GM or CD34+ cell counts may not be necessary if this MNC dose is reinfused.

KW - CFU-GM

KW - Engraftment

KW - Lymphoma

KW - MNC

KW - PBPC transplantation

UR - http://www.scopus.com/inward/record.url?scp=0029562009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029562009&partnerID=8YFLogxK

M3 - Article

C2 - 8542950

AN - SCOPUS:0029562009

VL - 23

SP - 1581

EP - 1588

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 14

ER -